Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
National Research Corp is a health information services business based in the US. National Research shares (NRC) are listed on the NASDAQ and all prices are listed in US Dollars. National Research employs 511 staff and has a trailing 12-month revenue of around $151.8 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $40.64 |
|---|---|
| 52-week range | $30.56 - $51.28 |
| 50-day moving average | $36.89 |
| 200-day moving average | $37.70 |
| Wall St. target price | N/A |
| PE ratio | 28.0282 |
| Dividend yield | $0.72 (1.78%) |
| Earnings per share (TTM) | $1.42 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $40.64 from 2022-10-03
| 1 week (2022-09-23) | 3.57% |
|---|---|
| 1 month (2022-08-31) | N/A |
| 3 months (2022-07-01) | 4.58% |
| 6 months (2022-03-31) | N/A |
| 1 year (2021-10-04) | -3.58% |
|---|---|
| 2 years (2020-10-02) | -20.80% |
| 3 years (2019-10-04) | 59.63 |
| 5 years (2017-10-04) | 7.37% |
Valuing National Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
National Research's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, National Research shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
National Research's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.7 million.
The EBITDA is a measure of a National Research's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $151.8 million |
|---|---|
| Operating margin TTM | 32.49% |
| Gross profit TTM | $95.6 million |
| Return on assets TTM | 21.4% |
| Return on equity TTM | 49.87% |
| Profit margin | 23.82% |
| Book value | $2.77 |
| Market capitalisation | $985.7 million |
TTM: trailing 12 months
Dividend payout ratio: 59.2% of net profits
Recently National Research has paid out, on average, around 59.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research shareholders could enjoy a 2.45% return on their shares, in the form of dividend payments. In National Research's case, that would currently equate to about $0.72 per share.
National Research's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
National Research's most recent dividend payout was on 14 October 2022. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2022 (the "ex-dividend date").
Over the last 12 months, National Research's shares have ranged in value from as little as $30.5599 up to $51.2756. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research's is 0.6772. This would suggest that National Research's shares are less volatile than average (for this exchange).
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.